INSUBCONTINENT EXCLUSIVE:
The document contains directional pricing information that will help us understand where the tech-enabled medical care startup expects the
market to value itself and also details its Q4 2019 Preliminary Estimated Unaudited Financial Results, which gives us a fuller picture of
upper-end of its proposed IPO range, represents a solid boost to its final private valuation
